These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2845276)

  • 21. Inhibition of natural killer cell cytotoxicity and interferon gamma production by the envelope protein of HIV and prevention by vasoactive intestinal peptide.
    Peruzzi M; Azzari C; Rossi ME; De Martino M; Vierucci A
    AIDS Res Hum Retroviruses; 2000 Jul; 16(11):1067-73. PubMed ID: 10933622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. gp120 as an etiologic agent for NeuroAIDS: neurotoxicity and model systems.
    Brenneman DE; McCune SK; Mervis RF; Hill JM
    Adv Neuroimmunol; 1994; 4(3):157-65. PubMed ID: 7874383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates.
    Hill JM; Mervis RF; Avidor R; Moody TW; Brenneman DE
    Brain Res; 1993 Feb; 603(2):222-33. PubMed ID: 8461978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VIP1-12 is a ligand for the CD4/human immunodeficiency virus receptor.
    Sacerdote P; Ruff MR; Pert CB
    Ann N Y Acad Sci; 1988; 527():574-8. PubMed ID: 2839089
    [No Abstract]   [Full Text] [Related]  

  • 25. Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?
    Veljkovic M; Branch DR; Dopsaj V; Veljkovic V; Veljkovic N; Glisic S; Colombatti A
    Med Hypotheses; 2011 Sep; 77(3):404-8. PubMed ID: 21684085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo depression of lymphocyte traffic in sheep by VIP and HIV (AIDS)-related peptides.
    Moore TC; Spruck CH; Said SI
    Immunopharmacology; 1988; 16(3):181-9. PubMed ID: 3267011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent gp120-like neurotoxic activity in the cerebrospinal fluid of HIV-infected individuals is blocked by peptide T.
    Buzy J; Brenneman DE; Pert CB; Martin A; Salazar A; Ruff MR
    Brain Res; 1992 Dec; 598(1-2):10-8. PubMed ID: 1486472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spectral and sequence similarity between vasoactive intestinal peptide and the second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120): possible consequences on prevention and therapy of AIDS.
    Veljkovic V; Metlas R; Raspopovic J; Pongor S
    Biochem Biophys Res Commun; 1992 Dec; 189(2):705-10. PubMed ID: 1472041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptor molecule blocks HIV.
    Weiss RA
    Nature; 1988 Jan; 331(6151):15. PubMed ID: 2829021
    [No Abstract]   [Full Text] [Related]  

  • 30. Human immunodeficiency virus glycoprotein (gp120) induction of monocyte arachidonic acid metabolites and interleukin 1.
    Wahl LM; Corcoran ML; Pyle SW; Arthur LO; Harel-Bellan A; Farrar WL
    Proc Natl Acad Sci U S A; 1989 Jan; 86(2):621-5. PubMed ID: 2536171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist.
    Glowa JR; Panlilio LV; Brenneman DE; Gozes I; Fridkin M; Hill JM
    Brain Res; 1992 Jan; 570(1-2):49-53. PubMed ID: 1617429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional interaction and partial homology between human immunodeficiency virus and neuroleukin.
    Lee MR; Ho DD; Gurney ME
    Science; 1987 Aug; 237(4818):1047-51. PubMed ID: 3039662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory influences of envelope glycoproteins of HIV-1 on normal immune responses.
    Chirmule N; Kalyanaraman V; Oyaizu N; Pahwa S
    J Acquir Immune Defic Syndr (1988); 1988; 1(5):425-30. PubMed ID: 2851650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemokines released from astroglia by vasoactive intestinal peptide. Mechanism of neuroprotection from HIV envelope protein toxicity.
    Brenneman DE; Hauser J; Spong CY; Phillips TM
    Ann N Y Acad Sci; 2000; 921():109-14. PubMed ID: 11193813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of human immunodeficiency virus recombinant envelope glycoprotein on immune cell functions in vitro.
    Shalaby MR; Krowka JF; Gregory TJ; Hirabayashi SE; McCabe SM; Kaufman DS; Stites DP; Ammann AJ
    Cell Immunol; 1987 Nov; 110(1):140-8. PubMed ID: 2824064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AIDS and its dementia as a neuropeptide disorder: role of VIP receptor blockade by human immunodeficiency virus envelope.
    Pert CB; Smith CC; Ruff MR; Hill JM
    Ann Neurol; 1988; 23 Suppl():S71-3. PubMed ID: 2831805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquired immune deficiency syndrome and the developing nervous system.
    Brenneman DE; McCune SK; Gozes I
    Int Rev Neurobiol; 1990; 32():305-53. PubMed ID: 1981886
    [No Abstract]   [Full Text] [Related]  

  • 38. Rescue of thymocytes from cell death by vasoactive intestinal peptide.
    Ernström U; Gafvelin G; Mutt V
    Regul Pept; 1995 May; 57(2):99-104. PubMed ID: 7659793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuronal glycolytic pathway impairment induced by HIV envelope glycoprotein gp120.
    Vignoli AL; Martini I; Haglid KG; Silvestroni L; Augusti-Tocco G; Biagioni S
    Mol Cell Biochem; 2000 Dec; 215(1-2):73-80. PubMed ID: 11204458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide.
    Brenneman DE; Glazner G; Hill JM; Hauser J; Davidson A; Gozes I
    Ann N Y Acad Sci; 1998 Dec; 865():207-12. PubMed ID: 9928014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.